Debevoise Named a “Regulatory Firm to Watch” by LMG Life Sciences

23 September 2021

Debevoise & Plimpton LLP has been named the “Regulatory Firm to Watch” by LMG Life Sciences in its annual awards ceremony which recognizes life sciences legal practitioners and firms behind the most complex and innovative life sciences work across corporate, regulatory, litigation and intellectual property matters from the past year.

The “Regulatory Firm to Watch” Award is given to select firms that have gained notable momentum in the life sciences industry through growth, high-profile client representations and practitioner expertise.  LMG Life Sciences determines its award results through a rigorous research process involving in-depth firm submissions, practitioner interviews, client feedback and independent research.

Paul D. Rubin, partner and co-chair of the firm’s Healthcare & Life Sciences Group was additionally shortlisted for LMG Life Sciences’ “FDA Pharmaceutical Regulatory Attorney of the Year” award for his outstanding work helping clients navigate the challenging FDA regulatory landscape. Other Debevoise partners recognized as LMG’s  “Life Sciences Stars” include Andrew Bab, Jennifer Chu, Mark Goodman, Ted Hassi (who was also recognized by LMG as the “2018 Antitrust Litigator of the Year”), Kevin Rinker, and of counsel (retired partner) Edwin Schallert.

The Debevoise Healthcare & Life Sciences Group employs a highly coordinated, multidisciplinary approach to address transactional, litigation, regulatory and intellectual property matters for leading healthcare & life sciences companies and for private equity firms investing in the industry. The team provides integrated, cross practice legal advice with efficient and seamless execution covering all aspects of healthcare & life sciences matters, including corporate and M&A, complex litigation and investigations, FDA/FTC regulatory, intellectual property, compliance and healthcare regulatory issues, and cybersecurity & data strategy.